Business Context and Reporting Period
This Form 8-K is a current report filed by Bicycle Therapeutics plc on March 17, 2026. The filing primarily serves to announce the appointment of a new Chief Operating Officer and to reference the release of financial results for the fiscal quarter and year ended December 31, 2025.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing financial results for the quarter and year ended December 31, 2025. However, the text of this 8-K does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Executive Appointments
The most significant material change reported is a leadership transition effective March 17, 2026:
- Appointment: Jennifer Perry, Pharm.D., has been appointed as Chief Operating Officer (COO).
- Transition: Dr. Perry succeeds Alistair Milnes, who will transition to the role of Chief Corporate Development Officer.
- Background: Dr. Perry previously served as Chief Strategy Officer and Head of Commercial since July 2024 and has over 20 years of experience in biotech and oncology.
Compensation and Employment Terms
Dr. Perry's new employment agreement includes the following key terms:
- Base Salary: $550,000 annually.
- Performance Bonus: Target annual cash bonus of 50% of base salary.
- Severance (Termination without cause/Good reason): Nine months of base salary and up to nine months of COBRA insurance.
- Change in Control Severance: If termination occurs within 12 months of a change in control, benefits increase to 18 months of base salary, 18 months of COBRA, a lump sum equal to the full annual target bonus, and full acceleration of unvested equity awards.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific financial metrics (revenue, cash position, R&D expenses) for the period ended December 31, 2025, as they are not detailed in this 8-K text.
- Verify the impact of the leadership change on the company's commercial strategy and pipeline execution.
- Monitor the upcoming Form 10-Q for the period ending March 31, 2026, which will contain the full text of Dr. Perry's employment agreement.
- Confirm the status of Alistair Milnes' transition to Chief Corporate Development Officer and any associated changes in corporate development activities.